<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="7508">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00918879</url>
  </required_header>
  <id_info>
    <org_study_id>D1680C00008</org_study_id>
    <nct_id>NCT00918879</nct_id>
  </id_info>
  <brief_title>Evaluate Saxagliptin in Adult Indian Patients With Type 2 Diabetes Inadequate Glycemic Control</brief_title>
  <official_title>A 24-Week National, Multi-centre, Randomized, Parallel-group, Double-blind, Placebo-controlled, Phase IIIb Study in India to Evaluate the Efficacy and Safety of Saxagliptin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycaemic Control With Diet and Exercise</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <authority>India: Drugs Controller General of India</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Saxagliptin is a new investigational medication being developed for treatment of type 2
      diabetes. This study is designed to evaluate the efficacy and safety in adult Indian
      patients with inadequate glycaemic control with diet and exercise.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Absolute Change From Baseline to Week 24 in Glycosylated Haemoglobin A1c (HbA1c)</measure>
    <time_frame>Baseline , Week 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>Adjusted* mean change from baseline in glycosylated haemoglobin A1c (HbA1c) achieved with saxagliptin 5 mg versus placebo at Week 24 (LOCF, Full Analysis set). HbA1c is a continuous measure, the change from baseline for each subject is calculated as the Week 24 values minus the baseline value. HbA1c data were excluded on and after rescue medication.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline to Week 24 in Fasting Plasma Glucose (FPG)</measure>
    <time_frame>Baseline , Week 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>Adjusted* mean change from baseline in fasting plasma glucose (FPG) achieved with saxagliptin 5 mg versus placebo at Week 24 (LOCF, Full Analysis set). FPG is a continuous measure, the change from baseline for each subject is calculated as the Week 24 values minus the baseline value. FPG data were excluded on and after rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients (Expressed in Percentage of Total Participants) Achieving a Therapeutic Glycemic Response Defined as HbA1c &lt; 7.0% at Week 24</measure>
    <time_frame>Baseline , Week 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>Proportion of participants (expressed in percentage of total participants)achieving HbA1c &lt; 7.0% for saxagliptin versus placebo at Week 24 (LOCF, Full Analysis set). HbA1c data were excluded on and after rescue medication</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">213</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Saxagliptin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saxagliptin</intervention_name>
    <description>Oral tablet, once daily for 24 weeks</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Onglyza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral tablet, once daily for 24 weeks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with Type 2 diabetes

          -  Patients should be drug naïve ie, not received medical treatment for diabetes

          -  HbA1c ≥ 7.2% and ≤10.0% (at enrolment), HbA1c ≥ 7.0% and ≤10.0% (at randomization)

        Exclusion Criteria:

          -  Insulin therapy within one year of enrolment (with the exception of insulin therapy
             during a hospitalization or use in gestational diabetes)

          -  Type 1 diabetes,history of ketoacidosis or hyperosmolar non-ketonic koma
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Ohman, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca, Wilmington, USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Deborah Price, MSc</last_name>
    <role>Study Chair</role>
    <affiliation>AstraZeneca, Wilmington, USA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gujarat</city>
        <state>Ahmedabad</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Karnataka</city>
        <state>Bangalore</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tamil Nadu</city>
        <state>Chennai</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tamil Nadu</city>
        <state>Coimbatore</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Andhra Pradesh</city>
        <state>Hyderabad</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madhya Pradesh</city>
        <state>Indore</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Haryana</city>
        <state>Karnal</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kerala</city>
        <state>Kochi</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Maharashtra</city>
        <state>Pune</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <lastchanged_date>August 18, 2011</lastchanged_date>
  <firstreceived_date>June 5, 2009</firstreceived_date>
  <firstreceived_results_date>June 28, 2011</firstreceived_results_date>
  <responsible_party>
    <name_title>AstraZeneca</name_title>
    <organization>AstraZeneca</organization>
  </responsible_party>
  <keyword>DPP-4 inhibitors</keyword>
  <keyword>HbA1c</keyword>
  <keyword>Incretins</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Saxagliptin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Saxagliptin 5 mg</title>
          <description>Saxagliptin 5 mg tablet, once daily( OD) for 24 weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo tablet, once daily( OD) for 24 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="107">Randomized and treated</participants>
                <participants group_id="P2" count="106">Randomized and treated</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="101">Completed 24 weeks of treatment</participants>
                <participants group_id="P2" count="100">Completed 24 weeks of treatment</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Severe non-compliance to protocol</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Saxagliptin 5 mg</title>
          <description>Saxagliptin 5 mg tablet, once daily( OD) for 24 weeks</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo tablet, once daily( OD) for 24 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="107"/>
                <measurement group_id="B2" value="106"/>
                <measurement group_id="B3" value="213"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="49.07" spread="8.77"/>
                <measurement group_id="B2" value="48.29" spread="9.59"/>
                <measurement group_id="B3" value="48.68" spread="9.17"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="50"/>
                <measurement group_id="B2" value="43"/>
                <measurement group_id="B3" value="93"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="57"/>
                <measurement group_id="B2" value="63"/>
                <measurement group_id="B3" value="120"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Absolute Change From Baseline to Week 24 in Glycosylated Haemoglobin A1c (HbA1c)</title>
        <description>Adjusted* mean change from baseline in glycosylated haemoglobin A1c (HbA1c) achieved with saxagliptin 5 mg versus placebo at Week 24 (LOCF, Full Analysis set). HbA1c is a continuous measure, the change from baseline for each subject is calculated as the Week 24 values minus the baseline value. HbA1c data were excluded on and after rescue medication.</description>
        <time_frame>Baseline , Week 24</time_frame>
        <safety_issue>No</safety_issue>
        <population>Randomized participants who took at least 1 dose of double-blind treatment. To be included in analysis of change from baseline to Wk 24(LOCF) for efficacy, subjects must have had a baseline and at least 1 post-baseline efficacy measurement. If participant received rescue medication, that measurement must have been taken before rescue.</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 5 mg</title>
            <description>Saxagliptin 5 mg tablet, once daily( OD) for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo tablet, once daily( OD) for 24 weeks</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="104"/>
                  <measurement group_id="O2" value="105"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Absolute Change From Baseline to Week 24 in Glycosylated Haemoglobin A1c (HbA1c)</title>
            <description>Adjusted* mean change from baseline in glycosylated haemoglobin A1c (HbA1c) achieved with saxagliptin 5 mg versus placebo at Week 24 (LOCF, Full Analysis set). HbA1c is a continuous measure, the change from baseline for each subject is calculated as the Week 24 values minus the baseline value. HbA1c data were excluded on and after rescue medication.</description>
            <units>percent</units>
            <param>Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <sub_title>Baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8.33" spread="0.080"/>
                  <measurement group_id="O2" value="8.33" spread="0.072"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 24</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.82" spread="0.116"/>
                  <measurement group_id="O2" value="8.28" spread="0.114"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Adjusted Change from Baseline to Week 24</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.51" spread="0.098"/>
                  <measurement group_id="O2" value="-0.05" spread="0.098"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.0011</p_value>
            <method>ANCOVA</method>
            <method_desc>* adjusted for baseline HbA1c</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.46</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.139</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.73</ci_lower_limit>
            <ci_upper_limit>-0.18</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline to Week 24 in Fasting Plasma Glucose (FPG)</title>
        <description>Adjusted* mean change from baseline in fasting plasma glucose (FPG) achieved with saxagliptin 5 mg versus placebo at Week 24 (LOCF, Full Analysis set). FPG is a continuous measure, the change from baseline for each subject is calculated as the Week 24 values minus the baseline value. FPG data were excluded on and after rescue medication.</description>
        <time_frame>Baseline , Week 24</time_frame>
        <safety_issue>No</safety_issue>
        <population>Randomized participants who took at least 1 dose of double-blind treatment. To be included in analysis of change from baseline to Wk 24(LOCF) for efficacy, subjects must have had a baseline and at least 1 post-baseline efficacy measurement. If participant received rescue medication, that measurement must have been taken before rescue.</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 5 mg</title>
            <description>Saxagliptin 5 mg tablet, once daily( OD) for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo tablet, once daily( OD) for 24 weeks</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="106"/>
                  <measurement group_id="O2" value="104"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Absolute Change From Baseline to Week 24 in Fasting Plasma Glucose (FPG)</title>
            <description>Adjusted* mean change from baseline in fasting plasma glucose (FPG) achieved with saxagliptin 5 mg versus placebo at Week 24 (LOCF, Full Analysis set). FPG is a continuous measure, the change from baseline for each subject is calculated as the Week 24 values minus the baseline value. FPG data were excluded on and after rescue medication.</description>
            <units>mg/dL</units>
            <param>Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <sub_title>Baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="150.77" spread="3.569"/>
                  <measurement group_id="O2" value="151.35" spread="3.693"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 24</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="140.58" spread="3.326"/>
                  <measurement group_id="O2" value="151.02" spread="4.833"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Adjusted Change from Baseline to Week 24</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-10.35" spread="3.827"/>
                  <measurement group_id="O2" value="-0.16" spread="3.863"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.0623</p_value>
            <method>ANCOVA</method>
            <method_desc>* Adjusted for baseline FPG</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-10.19</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.438</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-20.91</ci_lower_limit>
            <ci_upper_limit>0.53</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline to Week 24 in Fasting Plasma Glucose (FPG)</title>
        <description>Adjusted* mean change from baseline in fasting plasma glucose (FPG) achieved with saxagliptin 5 mg versus placebo at Week 24 (LOCF, Full Analysis set). FPG is a continuous measure, the change from baseline for each subject is calculated as the Week 24 values minus the baseline value. FPG data were excluded on and after rescue medication.</description>
        <time_frame>Baseline , Week 24</time_frame>
        <safety_issue>No</safety_issue>
        <population>Randomized participants who took at least 1 dose of double-blind treatment. To be included in analysis of change from baseline to Wk 24(LOCF) for efficacy, subjects must have had a baseline and at least 1 post-baseline efficacy measurement. If participant received rescue medication, that measurement must have been taken before rescue.</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 5 mg</title>
            <description>Saxagliptin 5 mg tablet, once daily( OD) for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo tablet, once daily( OD) for 24 weeks</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="106"/>
                  <measurement group_id="O2" value="104"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Absolute Change From Baseline to Week 24 in Fasting Plasma Glucose (FPG)</title>
            <description>Adjusted* mean change from baseline in fasting plasma glucose (FPG) achieved with saxagliptin 5 mg versus placebo at Week 24 (LOCF, Full Analysis set). FPG is a continuous measure, the change from baseline for each subject is calculated as the Week 24 values minus the baseline value. FPG data were excluded on and after rescue medication.</description>
            <units>mmol/L</units>
            <param>Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <sub_title>Baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8.37" spread="0.198"/>
                  <measurement group_id="O2" value="8.40" spread="0.205"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 24</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.80" spread="0.185"/>
                  <measurement group_id="O2" value="8.38" spread="0.268"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Adjusted Change from Baseline to Week 24</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.58" spread="0.212"/>
                  <measurement group_id="O2" value="-0.00" spread="0.214"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.0623</p_value>
            <method>ANCOVA</method>
            <method_desc>* Adjusted for baseline FPG</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.57</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.302</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.17</ci_lower_limit>
            <ci_upper_limit>0.02</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients (Expressed in Percentage of Total Participants) Achieving a Therapeutic Glycemic Response Defined as HbA1c &lt; 7.0% at Week 24</title>
        <description>Proportion of participants (expressed in percentage of total participants)achieving HbA1c &lt; 7.0% for saxagliptin versus placebo at Week 24 (LOCF, Full Analysis set). HbA1c data were excluded on and after rescue medication</description>
        <time_frame>Baseline , Week 24</time_frame>
        <safety_issue>No</safety_issue>
        <population>Randomized participants who took at least 1 dose of double-blind treatment. To be included in analysis of change from baseline to Wk 24(LOCF) for efficacy, subjects must have had a baseline and at least 1 post-baseline efficacy measurement. If participant received rescue medication, that measurement must have been taken before rescue.</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 5 mg</title>
            <description>Saxagliptin 5 mg tablet, once daily( OD) for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo tablet, once daily( OD) for 24 weeks</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="104"/>
                  <measurement group_id="O2" value="105"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Proportion of Patients (Expressed in Percentage of Total Participants) Achieving a Therapeutic Glycemic Response Defined as HbA1c &lt; 7.0% at Week 24</title>
            <description>Proportion of participants (expressed in percentage of total participants)achieving HbA1c &lt; 7.0% for saxagliptin versus placebo at Week 24 (LOCF, Full Analysis set). HbA1c data were excluded on and after rescue medication</description>
            <units>Percentage of Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="22.1"/>
                  <measurement group_id="O2" value="13.3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>8.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.7</ci_lower_limit>
            <ci_upper_limit>19.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Saxagliptin 5 mg</title>
          <description>Saxagliptin 5 mg tablet, once daily( OD) for 24 weeks</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo tablet, once daily( OD) for 24 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gerard Lynch</name_or_title>
      <organization>AstraZeneca</organization>
      <email>aztrial_results_posting@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
